1. Male/Female must be 18-
Conditions
Interventions
None listed
Sponsors
Ranbaxy (Thailand) Co., Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Male/Female must be 18-55 years of age, body mass index (BMI) = 18-25 kg/m2, inclusive. 2. Must be in good health as determined by medical history, vital signs, and physical examination. 3. Screening ECG without clinically significant abnormalities. 4. Screening visit Laboratory values of blood test including haematology(complete blood count (CBC) with differential), Fasting Blood Sugar(FBS), Blood Urea Nitrogen (BUN), Creatinine (Cr) analysis, Creatine phosphokinase (CPK) and liver function test (aspartate aminotransferase (AST)/alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, direct bilirubin, albumin, total protein) must be within the normal range or showing no clinically significant abnormalities in the opinion of clinical investigator. 5. Urinalysis results within normal limit or showing no clinically significant abnormalities in the opinion of clinical investigator. 6. Must have negative results of serum hepatitis B surface antigen (HbsAg), hepatitis C virus antibody (anti-HCV) and venereal disease research laboratory (VDRL). 7. Must have negative results of urine drug abuse testing of methamphetamine, cannabinoids (Tetrahydrocannabinol), cocaine, MDMA (3,4-methylenedioxy-methamphetamine), and opioids (morphine and methadone) 8. Female subjects must have serum β-HCG negative. 9. Female subject who is childbearing potential agrees to use an acceptable birth control method from visit 1 to the follow up visit. The acceptable birth control method is defined as a barrier method of contraception (including condoms, intrauterine device (IUD), and diaphragm with spermicidal agent) or total abstinence from sexual intercourse from visit 1 to the follow up visit. Hormonal contraceptives are not acceptable. 10. Female subject who is non-childbearing potential (hysterectomy, both ovaries removed, surgically sterilized or postmenopausal (for at least 12 consecutive months of amenorrhea)). 11. Female subjects must agree not to become pregnant for the entire participation period and must have a negative result for a urine pregnancy test performing prior to dosing at period I, II, III and period IV. 12. Non-smokers (never smoked or no smoking within the previous 2 years). 13. Refrain from using herbal medications, dietary supplements (e.g., St.John’s Wort, ginkgo biloba, garlic supplements), vitamins, grapefruit or grapefruit juice, or pomelo within 14 days before the first administration of study drug (Day 1). Subjects must refrain from these items until the last collection time-point of period IV. 14. Subjects must have ended any medications at least 1 month prior to Day 1 and agree to continue their refraining throughout the follow up period. 15. Subjects must refrain from drinking caffeine and alcohol for at least 72 hours and one month, respectively prior to Day 1 and agree to continue their refraining throughout the last collection time-point of period IV. 16. Have the ability to understand the requirements of the study and must voluntarily sign and date an informed consent, approved by an Independent Ethic Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.
Exclusion criteria
Exclusion criteria: 1. Known hypersensitivity to atorvastatin and its components. 2. Past medical history of renal and hepatic insufficiency. 3. Subject has a history of any illness that, in the opinion of the investigator, might confound the result of the study or pose an additional risk in administering study drug to the subject. This may include but is not limited to: a history of relevant drug or food allergies; history of cardiovascular, gastrointestinal, central nervous system disease, renal and hepatic impairment; history or presence of clinically significant illness; or history of mental illness that may affect compliance with study requirements. 4. Have history of drug abuse in the last 12 months. 5. Alcohol abuse or excessive use (in the opinion of the investigator, as judged by medical history) in the last 12 months. 6. Female subject is pregnant or breast feeding. 7. Donation or loss of whole blood: a. ≥ 50 mL and ≤ 499 mL within 30 days prior to dosing b. ≥ 500 mL within 56 days prior to dosing. 8. Participation in any investigation drug study within 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bioequivalence pre-dose (in duplicate) and, 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.50, 3.00, PK measurement | — |
Secondary
| Measure | Time frame |
|---|---|
| womac score Baseline and post intervention at 1,4 and 12 week Womac score,Timing of gait Baseline and post intervention at 1,4 and 12 week Time up and go test | — |
Countries
Thailand
Contacts
Public ContactNoppamas Rojanasthien
Faculty of Medicine, Chiang Mai University
Outcome results
None listed